Percheron Therapeutics Ltd. engages in the research and development of novel antisense pharmacceuticals. It operates through the following segments: ATL1102 and HMBD-002. The ATL1102 segment represents the second generation antisense inhibitor of CD49d, the alpha subunit of very late antigen-four. The HMBD-002 segment refers to a recombinant, humanised monoclonal IgG4 antibody to human v-domain immunoglobulin suppressor of T-cell activation (VISTA). The company was founded on November 13, 2000 and is headquartered in Toorak, Australia.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Percheron Therapeutics Ltd. market cap is $4.76M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Percheron Therapeutics Ltd. 52 week high is $0.005 as of November 18, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Percheron Therapeutics Ltd. 52 week low is $0.0011 as of November 18, 2026.
Percheron Therapeutics Ltd. stock price today is $0.0024.
Percheron Therapeutics Ltd. stock price yesterday was $0.0024.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Percheron Therapeutics Ltd.'s P/E ratio is -0.89.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Percheron Therapeutics Ltd. P/B ratio is 0.6997.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Percheron Therapeutics Ltd. 50-day moving average is $0.0024.